These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 657151

  • 61. Effect and toxicity of combination treatment including cyclocytidine or cytosine arabinoside in L-1210 and sarcoma-180 systems.
    Hoshi A, Kanzawa F, Iigo M, Kuretani K.
    Gan; 1975 Oct; 66(5):539-46. PubMed ID: 1220992
    [Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210.
    Kobayashi T, Tsukagoshi S, Sakurai Y.
    Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724
    [No Abstract] [Full Text] [Related]

  • 66. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
    Ho DH, Frei E.
    Clin Pharmacol Ther; 1971 Dec; 12(6):944-54. PubMed ID: 5289712
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line.
    El-Beltagi HM, Martens AC, Hagenbeek A.
    Leukemia; 2000 Jan; 14(1):213-4. PubMed ID: 10637498
    [No Abstract] [Full Text] [Related]

  • 69. ACTIVITY OF SELECTED COMPOUNDS IN SUBLINE OF LEUKEMIA L1210 RESISTANT TO CYTOSINE ARABINOSIDE (NSC-63878).
    WODINSKY I, KENSLER CJ.
    Cancer Chemother Rep; 1964 Dec; 43():1-3. PubMed ID: 14250647
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Effect of reserpine (NSC-59272)-induced hypothermia on lifespan in mouse L1210 leukemia.
    Fondy TP, Karker KL, Calcagnino C, Emlich CA.
    Cancer Chemother Rep; 1974 Dec; 58(3):317-24. PubMed ID: 4841715
    [No Abstract] [Full Text] [Related]

  • 72. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
    Fu JC, Khwaja T, Moyer DL, Cummings L, Varvan J, Elshire D.
    J Surg Oncol; 1978 Dec; 10(1):1-7. PubMed ID: 628213
    [Abstract] [Full Text] [Related]

  • 73. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside.
    Kessel D, Hall TC, Wodinsky I.
    Science; 1967 Jun 02; 156(3779):1240-1. PubMed ID: 6025544
    [Abstract] [Full Text] [Related]

  • 74. Effects of adriamycin and daunomycin on spleen cell populations in normal and tumor allografted mice.
    Mantovani A, Tagliabue A, Vecchi A, Spreafico F.
    Eur J Cancer (1965); 1976 May 02; 12(5):381-7. PubMed ID: 1085252
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Ultrasonic enhancement of nitrogen mustard cytotoxicity in mouse leukemia.
    Kremkau FW, Kaufmann JS, Walker MM, Burch PG, Spurr CL.
    Cancer; 1976 Apr 02; 37(4):1643-7. PubMed ID: 1260681
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Protection of intestinal damage by pretreatment with cytarabine (cytosine arabinoside).
    Phelps TA, Blackett NM.
    Int J Radiat Oncol Biol Phys; 1979 Sep 02; 5(9):1617-20. PubMed ID: 536270
    [No Abstract] [Full Text] [Related]

  • 79. Polylysine-drug conjugates.
    Arnold LJ.
    Methods Enzymol; 1985 Sep 02; 112():270-85. PubMed ID: 3862928
    [No Abstract] [Full Text] [Related]

  • 80. Detection of induced resistance to cytosine-arabinoside with a short-term test.
    Volm M, Maas E, Mattern J.
    Eur J Cancer (1965); 1980 May 02; 16(5):733-6. PubMed ID: 7389798
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.